A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects.
JAK/STAT3 signaling pathway
STAT3 inhibitors
ageladine A derivatives
antitumor activities
antitumor mechanisms
dibromo pyrrole-imidazole
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 May 2023
16 May 2023
Historique:
received:
06
03
2023
revised:
21
04
2023
accepted:
11
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
The Janus kinase/signal transducer and activator of the transcription 3 (JAK/STAT3) signaling pathway controls multiple biological processes, including cell survival, proliferation, and differentiation. Abnormally activated STAT3 signaling promotes tumor cell growth, proliferation, and survival, as well as tumor invasion, angiogenesis, and immunosuppression. Hence, JAK/STAT3 signaling has been considered a promising target for antitumor therapy. In this study, a number of ageladine A derivative compounds were synthesized. The most effective of these was found to be compound
Identifiants
pubmed: 37240202
pii: ijms24108859
doi: 10.3390/ijms24108859
pmc: PMC10219297
pii:
doi:
Substances chimiques
Ageladine A
0
Janus Kinases
EC 2.7.10.2
STAT3 Transcription Factor
0
STAT3 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Tao Jiang
ID : 82073759; 82122064; IPM2021C009; No.2022QNLM030003
Références
Acta Pharmacol Sin. 2022 Apr;43(4):1013-1023
pubmed: 34267347
MedComm (2020). 2022 Mar 23;3(2):e124
pubmed: 35356799
Pharmacol Res. 2019 Sep;147:104373
pubmed: 31351913
Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270
pubmed: 29397354
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Int J Mol Sci. 2021 Feb 28;22(5):
pubmed: 33671049
Science. 1994 Jun 3;264(5164):1415-21
pubmed: 8197455
Hum Mol Genet. 2017 Aug 1;26(15):2949-2960
pubmed: 28486600
Clin Cancer Res. 2017 Sep 15;23(18):5537-5546
pubmed: 28533225
PLoS One. 2013 May 21;8(5):e63697
pubmed: 23704931
Org Lett. 2006 Mar 30;8(7):1443-6
pubmed: 16562912
J Invest Dermatol. 2011 Jan;131(1):108-17
pubmed: 20811392
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
Arch Pharm Res. 2016 Aug;39(8):1085-99
pubmed: 27515050
Oncogene. 2021 Feb;40(8):1440-1457
pubmed: 33420372
J Med Chem. 2021 Jul 8;64(13):8884-8915
pubmed: 34170703
Int J Cancer. 2012 Jul 1;131(1):8-17
pubmed: 21792892
Org Lett. 2006 Aug 31;8(18):4083-4
pubmed: 16928079
Semin Cancer Biol. 2021 Jan;68:31-46
pubmed: 31711994
Org Lett. 2016 Feb 19;18(4):704-7
pubmed: 26829876
Drugs. 2017 Apr;77(5):521-546
pubmed: 28255960
Mar Drugs. 2012 Jan;10(1):223-233
pubmed: 22363232
Theranostics. 2019 Aug 14;9(22):6424-6442
pubmed: 31588227
Signal Transduct Target Ther. 2021 Nov 26;6(1):402
pubmed: 34824210
Cell Prolif. 2021 Feb;54(2):e12974
pubmed: 33382511
J Am Chem Soc. 2003 Dec 24;125(51):15700-1
pubmed: 14677933
Curr Opin Immunol. 2015 Jun;34:75-82
pubmed: 25749511
ACS Chem Biol. 2016 Feb 19;11(2):308-18
pubmed: 26730496
Mol Cancer. 2020 Sep 24;19(1):145
pubmed: 32972405
Int Immunol. 2021 Mar 1;33(3):127-148
pubmed: 33337480
Pharmacol Res. 2016 Sep;111:784-803
pubmed: 27473820
Eur J Med Chem. 2014 Jul 23;82:195-203
pubmed: 24904966
Pharmacol Ther. 2018 Nov;191:74-91
pubmed: 29933035
Expert Opin Investig Drugs. 2017 Aug;26(8):883-887
pubmed: 28714740